Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.70 |
| ▸ | CA12 | O43570 | 3/20 | 0.70 |
| ▸ | CA1 | P00915 | 3/20 | 0.70 |
| ▸ | CA2 | P00918 | 3/20 | 0.70 |
| ▸ | CA3 | P07451 | 3/20 | 0.70 |
| ▸ | CA4 | P22748 | 3/20 | 0.70 |
| ▸ | CA6 | P23280 | 3/20 | 0.70 |
| ▸ | CA5A | P35218 | 3/20 | 0.70 |
| ▸ | CA7 | P43166 | 3/20 | 0.70 |
| ▸ | CA9 | Q16790 | 3/20 | 0.70 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.70 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.70 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.70 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.70 |
| ▸ | BACE1 | P56817 | 2/20 | 0.70 |
| ▸ | DPP4 | P27487 | 2/20 | 0.70 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.70 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6022871 | 1.00 | KDM4E (0.70) | KDM4ECA12CA1CA2CA3 | |
| SCHEMBL8250863 | 0.86 | HDAC2 (0.73) | KDM4ECA12CA1CA2CA3 | |
| SCHEMBL2260712 | 0.85 | KDM4E (0.70) | KDM4ECA12CA1CA2CA3 | |
| SCHEMBL2260713 | 0.85 | KDM4E (0.70) | KDM4ECA12CA1CA2CA3 | |
| SCHEMBL7828903 | 0.85 | PYGL (0.62) | KDM4ECA12CA1CA2CA3 | |
| SCHEMBL1124517 | 0.85 | PYGL (0.62) | KDM4ECA12CA1CA2CA3 | |
| SCHEMBL1124516 | 0.85 | PYGL (0.62) | KDM4ECA12CA1CA2CA3 | |
| Coumaric Acid SCHEMBL8075052 | 0.84 | CA12 (0.64) | KDM4ECA12CA1CA2CA3 | |
| Coumaric Acid SCHEMBL8075058 | 0.84 | CA12 (0.64) | KDM4ECA12CA1CA2CA3 | |
| SCHEMBL3223975 | 0.84 | BACE1 (0.88) | KDM4ECA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119709577-A | Recombinant strain for expressing phenolic acid decarboxylase as well as construction method and application thereof | 南京工业大学 | 2025-03-28 | — | — | CN | disclosed |
| CN-113880695-A | Preparation method of 4-vinylphenol compound | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 2022-01-04 | — | — | CN | disclosed |
| EP-3271465-B1 | METHOD FOR PRODUCING P-VINYLPHENOLS | UNIV GRAZ (AT) | 2019-09-11 | — | — | EP | disclosed |
| US-20180057845-A1 | METHOD FOR PREPARING p-VINYL PHENOLS | UNIVERSITAET GRAZ (AT) | 2018-03-01 | — | — | US | disclosed |
| CN-107532184-A | A kind of method for preparing 4-Vinyl phenol | 格拉茨大学 | 2018-01-02 | — | — | CN | disclosed |
| EP-2528897-B9 | DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMA CO LTD (JP) | 2015-04-22 | — | — | EP | disclosed |
| EP-2528897-B1 | DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMA CO LTD (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-8722663-B2 | Di-substituted pyridine derivatives as anticancers | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-05-13 | — | — | US | disclosed |
| EP-2528897-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2012-12-05 | — | — | EP | disclosed |
| US-20120283242-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-11-08 | — | — | US | disclosed |
| WO-2011093524-A9 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-12-01 | — | — | WO | disclosed |
| US-7053071-B2 | For therapy of leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells | THE BURNHAM INSTITUTE (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1456165-A1 | INDUCTION OF APOPTOSIS IN CANCER CELLS | The Burnham Institute (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20030176506-A1 | Induction of apoptosis in cancer cells | BURNHAM INSTITUTE FOR MEDICAL RESEARCH | 2003-09-18 | — | — | US | disclosed |
| WO-2003048101-A1 | INDUCTION OF APOPTOSIS IN CANCER CELLS | THE BURNHAM INSTITUTE (US) | 2003-06-12 | — | — | WO | disclosed |
| US-5681689-A | COUPLING WITH OXIDIZED COLOR DEVELOPER | EASTMAN KODAK COMPANY (US) | 1997-10-28 | — | — | US | disclosed |
| US-4038414-A | ANTIARRHYTHMIA AGENTS | CIBA-GEIGY CORPORATION (US) | 1977-07-26 | — | — | US | disclosed |
| US-4014920-A | N-cinnamylcarbamic acid esters | CIBA-GEIGY CORPORATION (US) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057845-A1 | METHOD FOR PREPARING p-VINYL PHENOLS | PAH, TH, HPD | KDM4E 315/4885CA12 2060/4885CA1 1288/4885 |
| US-20030176506-A1 | Induction of apoptosis in cancer cells | MCL1, BAD, BCL2 | KDM4E 2860/4885CA12 2413/4885CA1 1420/4885 |
| US-20120283242-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | TPD52L2, CCNE2, CDK2 | KDM4E 719/4885CA12 4010/4885CA1 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.